Orientations
Pneumococcal Vaccine: Handling the change in product manufacturer and presentation
Summary guidance for national authorities and immunization programme managers for the switch from GlaxoSmithKline Biologicals SA Synflorix® (PCV 10) to Pfizer Prevenar13® vaccine (PCV 13)
Auteurs
Langues
- Portuguais
Année de publication
2017
Éditeur
World Health Organization
Type
Orientations
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Infection à pneumocoque
Références sur le sujet
EPI-CORE-PNEUMO
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| Characteristics of different presentations of Pneumococcal Conjugate Vaccines | World Health Organization (WHO) | 2017 | Poster/infographic | Anglais |
| Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs) | Gavi, the Vaccine Alliance | 2017 | Guidance | Anglais |
| Pneumococcal Vaccine: Handling the change in product manufacturer and presentation | World Health Organization (WHO) | 2017 | Guidance | Portuguais |
